Innovative retatrutide, a dual -action drug targeting both GLP-1 and GIP receptors, is generating considerable interest within the medical community. Initial clinical studies have shown significant losses in physical size and improvements in physiological markers for people with obesity . Experts believe this novel approach may mark a key break… Read More